Role of L-carnitine in treating myopathy and peripheral neuropathy caused by paclitaxel in breast cancer patients.

Effectiveness of L-carnitine on paclitaxel induced myopathy and peripheral neuropathy in breast cancer patients : A randomized, double blind, placebo-controlled trail. - -

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/03/064164

Enrollment

Registered

2024-03-14

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: Paclitaxel+L-carnitine: Dose - 500mg Frequency- thrice daily for 6 months. Control Intervention1: Paclitaxel + placebo: Dose - 500mg Frequency- thrice daily for 6 months

Eligibility

Inclusion criteria

Inclusion criteria: 1.patients with pre-existing myopathy and peripheral neuropathy induced by paclitaxel and those have high risk for developing these are included. 2.patients willing to give informed consent

Exclusion criteria

Exclusion criteria: 1.patients with history of ESRD and are excluded. 2.patients with peripheral neuropathy and myopathy precipitated by other disease and drugs are excluded.

Design outcomes

Primary

Measure	Time frame
Serum Creatine kinase MM (CK MM) and Nerve conduction studyTimepoint: Baseline and week 26	—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactDr T M Vijayakumar

SRM COLLEGE OF PHARMACY, SRMIST

Vijaypractice@yahoo.com9003400350

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026